Reply to "Vaccination caused underestimation of cumulative incidence of SARS-CoV-2 infection"

doi:10.1128/spectrum.01979-24

. 2025 Feb 4;13(2):e0197924.

doi: 10.1128/spectrum.01979-24. Epub 2024 Dec 16.

Reply to "Vaccination caused underestimation of cumulative incidence of SARS-CoV-2 infection"

Jefferson M Jones¹, Melissa M Coughlin¹, Eduard Grebe², Michael P Busch², Kristie E N Clarke³

Affiliations

¹ National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
² Vitalant Research Institute, San Francisco, California, USA.
³ Office of Public Health Data, Surveillance, and Technology, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.

PMID: 39679675
PMCID: PMC11792466
DOI: 10.1128/spectrum.01979-24

Reply to "Vaccination caused underestimation of cumulative incidence of SARS-CoV-2 infection"

Jefferson M Jones et al. Microbiol Spectr. 2025.

. 2025 Feb 4;13(2):e0197924.

doi: 10.1128/spectrum.01979-24. Epub 2024 Dec 16.

Authors

Jefferson M Jones¹, Melissa M Coughlin¹, Eduard Grebe², Michael P Busch², Kristie E N Clarke³

Affiliations

¹ National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
² Vitalant Research Institute, San Francisco, California, USA.
³ Office of Public Health Data, Surveillance, and Technology, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.

PMID: 39679675
PMCID: PMC11792466
DOI: 10.1128/spectrum.01979-24

No abstract available

Keywords: SARS-CoV-2; serology; seroprevalence; serosurveillance; vaccines.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

References

1. Kao S-YZ, Nycz E, Benoit TJ, Clarke KEN, Jones JM. 2024. Comparison of SARS-CoV-2 seroprevalence estimates between commercial lab serum specimens and blood donor specimens, United States, September-December 2021. Microbiol Spectr 12:e0012324. doi:10.1128/spectrum.00123-24 - DOI - PMC - PubMed
1. Follmann D, Janes HE, Buhule OD, Zhou H, Girard B, Marks K, Kotloff K, Desjardins M, Corey L, Neuzil KM, Miller JM, El Sahly HM, Baden LR. 2022. Antinucleocapsid antibodies after SARS-CoV-2 infection in the blinded phase of the randomized, placebo-controlled mRNA-1273 COVID-19 vaccine efficacy clinical trial. Ann Intern Med 175:1258–1265. doi:10.7326/M22-1300 - DOI - PMC - PubMed
1. Grebe E, Stone M, Spencer BR, Akinseye A, Wright D, Di Germanio C, Bruhn R, Zurita KG, Contestable P, Green V, Lanteri MC, Saa P, Biggerstaff BJ, Coughlin MM, Kleinman S, Custer B, Jones JM, Busch MP. 2024. Detection of nucleocapsid antibodies associated with primary SARS-CoV-2 infection in unvaccinated and vaccinated blood donors. Emerg Infect Dis 30:1621–1630. doi:10.3201/eid3008.240659 - DOI - PMC - PubMed
1. Sulaeman H, Grebe E, Dave H, McCann L, Di Germanio C, Sanghavi A, Sclar V, Bougie DW, Chatelain G, Biggerstaff BJ, Jones JM, Thornburg NJ, Kleinman S, Stone M, Busch MP. 2023. Evaluation of ortho VITROS and roche Elecsys S and NC immunoassays for SARS-CoV-2 serosurveillance applications. Microbiol Spectr 11:e0323422. doi:10.1128/spectrum.03234-22 - DOI - PMC - PubMed
1. Mizoue T, Yamamoto S, Konishi M, Oshiro Y, Inamura N, Nemoto T, Ozeki M, Horii K, Okudera K, Sugiyama H, Aoyanagi N, Sugiura W, Ohmagari N. 2022. Sensitivity of anti-SARS-CoV-2 nucleocapsid protein antibody for breakthrough infections during the epidemic of the Omicron variants. J Infect 85:573–607. doi:10.1016/j.jinf.2022.08.015 - DOI - PMC - PubMed

Grants and funding

HHS | Centers for Disease Control and Prevention (CDC)

LinkOut - more resources

Full Text Sources
- Atypon
- PubMed Central
Miscellaneous
- NCI CPTAC Assay Portal

[1] Kao S-YZ, Nycz E, Benoit TJ, Clarke KEN, Jones JM. 2024. Comparison of SARS-CoV-2 seroprevalence estimates between commercial lab serum specimens and blood donor specimens, United States, September-December 2021. Microbiol Spectr 12:e0012324. doi:10.1128/spectrum.00123-24 - DOI - PMC - PubMed

[2] Kao S-YZ, Nycz E, Benoit TJ, Clarke KEN, Jones JM. 2024. Comparison of SARS-CoV-2 seroprevalence estimates between commercial lab serum specimens and blood donor specimens, United States, September-December 2021. Microbiol Spectr 12:e0012324. doi:10.1128/spectrum.00123-24 - DOI - PMC - PubMed

[3] Follmann D, Janes HE, Buhule OD, Zhou H, Girard B, Marks K, Kotloff K, Desjardins M, Corey L, Neuzil KM, Miller JM, El Sahly HM, Baden LR. 2022. Antinucleocapsid antibodies after SARS-CoV-2 infection in the blinded phase of the randomized, placebo-controlled mRNA-1273 COVID-19 vaccine efficacy clinical trial. Ann Intern Med 175:1258–1265. doi:10.7326/M22-1300 - DOI - PMC - PubMed

[4] Follmann D, Janes HE, Buhule OD, Zhou H, Girard B, Marks K, Kotloff K, Desjardins M, Corey L, Neuzil KM, Miller JM, El Sahly HM, Baden LR. 2022. Antinucleocapsid antibodies after SARS-CoV-2 infection in the blinded phase of the randomized, placebo-controlled mRNA-1273 COVID-19 vaccine efficacy clinical trial. Ann Intern Med 175:1258–1265. doi:10.7326/M22-1300 - DOI - PMC - PubMed

[5] Grebe E, Stone M, Spencer BR, Akinseye A, Wright D, Di Germanio C, Bruhn R, Zurita KG, Contestable P, Green V, Lanteri MC, Saa P, Biggerstaff BJ, Coughlin MM, Kleinman S, Custer B, Jones JM, Busch MP. 2024. Detection of nucleocapsid antibodies associated with primary SARS-CoV-2 infection in unvaccinated and vaccinated blood donors. Emerg Infect Dis 30:1621–1630. doi:10.3201/eid3008.240659 - DOI - PMC - PubMed

[6] Grebe E, Stone M, Spencer BR, Akinseye A, Wright D, Di Germanio C, Bruhn R, Zurita KG, Contestable P, Green V, Lanteri MC, Saa P, Biggerstaff BJ, Coughlin MM, Kleinman S, Custer B, Jones JM, Busch MP. 2024. Detection of nucleocapsid antibodies associated with primary SARS-CoV-2 infection in unvaccinated and vaccinated blood donors. Emerg Infect Dis 30:1621–1630. doi:10.3201/eid3008.240659 - DOI - PMC - PubMed

[7] Sulaeman H, Grebe E, Dave H, McCann L, Di Germanio C, Sanghavi A, Sclar V, Bougie DW, Chatelain G, Biggerstaff BJ, Jones JM, Thornburg NJ, Kleinman S, Stone M, Busch MP. 2023. Evaluation of ortho VITROS and roche Elecsys S and NC immunoassays for SARS-CoV-2 serosurveillance applications. Microbiol Spectr 11:e0323422. doi:10.1128/spectrum.03234-22 - DOI - PMC - PubMed

[8] Sulaeman H, Grebe E, Dave H, McCann L, Di Germanio C, Sanghavi A, Sclar V, Bougie DW, Chatelain G, Biggerstaff BJ, Jones JM, Thornburg NJ, Kleinman S, Stone M, Busch MP. 2023. Evaluation of ortho VITROS and roche Elecsys S and NC immunoassays for SARS-CoV-2 serosurveillance applications. Microbiol Spectr 11:e0323422. doi:10.1128/spectrum.03234-22 - DOI - PMC - PubMed

[9] Mizoue T, Yamamoto S, Konishi M, Oshiro Y, Inamura N, Nemoto T, Ozeki M, Horii K, Okudera K, Sugiyama H, Aoyanagi N, Sugiura W, Ohmagari N. 2022. Sensitivity of anti-SARS-CoV-2 nucleocapsid protein antibody for breakthrough infections during the epidemic of the Omicron variants. J Infect 85:573–607. doi:10.1016/j.jinf.2022.08.015 - DOI - PMC - PubMed

[10] Mizoue T, Yamamoto S, Konishi M, Oshiro Y, Inamura N, Nemoto T, Ozeki M, Horii K, Okudera K, Sugiyama H, Aoyanagi N, Sugiura W, Ohmagari N. 2022. Sensitivity of anti-SARS-CoV-2 nucleocapsid protein antibody for breakthrough infections during the epidemic of the Omicron variants. J Infect 85:573–607. doi:10.1016/j.jinf.2022.08.015 - DOI - PMC - PubMed

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Reply to "Vaccination caused underestimation of cumulative incidence of SARS-CoV-2 infection"

Affiliations

Reply to "Vaccination caused underestimation of cumulative incidence of SARS-CoV-2 infection"

Authors

Affiliations

Conflict of interest statement

Similar articles

References

Grants and funding

LinkOut - more resources

Full Text Sources

Miscellaneous